It isn't just that there are statistics. You're absolutely right that we would extrapolate to Canada the international figures, so you're looking at maybe 28 million Canadians who could be affected.
Very important as to why we need this regulatory framework and why we need to focus the research and development is that there are, as I think Dr. Fry was mentioning, ethnic pockets in Canada, and there are also geographically isolated pockets in Canada. So we are actually the host of some rare diseases that are most prevalent or most well identified in Canada. So unless we're doing the research on treatments for these diseases, these treatments aren't going to be developed elsewhere, and we offer a great opportunity to do the research here.
The bone disease I was talking about is prevalent among Amish communities. A small community outside of Winnipeg is actually the site for one of the clinical trials. So it's not just the sheer numbers but the recognition that many of these diseases will become prevalent because of the geographic isolation. We in Canada are actually home to some very unique rare diseases, or we have a large population, because of ethnic migration, of some of these rare diseases. So it's a great opportunity for us not just to deal with numbers, but also to deal specifically with some of those diseases that are either overrepresented or easily identified in Canada.